仁和药业: 股票交易异常波动公告

Group 1 - The company's stock experienced an abnormal trading fluctuation, with a cumulative closing price increase of over 20.42% on August 20 and 21, 2025 [1] - The company confirmed that there are no undisclosed significant matters or information that should have been disclosed according to the Shenzhen Stock Exchange regulations [2] - The company is currently developing a product in collaboration with Shenzhen Biaiai Intelligent Medical Technology Co., Ltd., aimed at addressing youth issues such as myopia prevention, mental health, and focus enhancement [1][2] Group 2 - The product is still in the sample production stage and is undergoing trial testing in select eyewear stores, with no significant impact on the company's current performance [2] - The technology of the product differs significantly from the rumored brain-machine interface technology involving internal brain chip implantation [2] - The company plans to disclose its 2025 semi-annual report on August 26, 2025, with ongoing preparations for the financial data [2]